Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On July 20, 2022, Patrick F. Kelly, M.D., Senior Vice President and Chief Medical Officer, and a named executive officer, of Forma Therapeutics Holdings, Inc. (the "Company") provided notice of his resignation from employment with the Company, effective August 3, 2022 (the "Separation Date"). In connection with his resignation, Dr. Kelly and the Company entered into a Transition and General Release Agreement on July 22, 2022 (the "Transition Agreement") pursuant to which Dr. Kelly (i) will receive compensation equal to his current base salary ($471,215 in the aggregate) over a period of 12 months following the Separation Date and (ii) provided a release of claims against the Company. As provided in the Transition Agreement, Dr. Kelly and the Company also entered into a consulting agreement (the "Consulting Agreement") on such date in which Dr. Kelly agrees to provide consulting services to the Company for 3 months beginning August 4, 2022 for compensation of $12,687 per month, as well as reasonable travel and other expenses incurred in providing such services. During the term of the Consulting Agreement, Dr. Kelly's current outstanding unvested equity grants shall continue to vest.

Also on July 20, 2022, Selwyn Vickers, M.D., notified the Company of his intent to resign from the Company's Board of Directors (the "Board"), effective July 31, 2022. Dr. Vickers' decision to resign from the Board was not the result of any dispute or disagreement with the Company or the Company's Board on any matter relating to the Company's operations, policies or practices.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses